Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
RANCHO CORDOVA, Calif., April 11, 2017 -- Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim Chief Executive Officer and Chairman of Boyalife Group, will present an overview of the Company’s cardiovascular clinical research program at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair, being held April 10-12, 2017 at the Hope Hotel in Shanghai, China.
Details of the presentation are as follows:
| Title: | Autologous Stem Cell Applications in Critical Limb Ischemia and Myocardial Infarction |
| Session: | Stem Cells and Tissue Engineering in Preclinical Studies |
| Location: | Hope Hotel, Chengxia Room, 5th Floor |
| Date: | Wednesday, April 12, 2017 |
| Time: | 4:40pm – 5:00pm CST |
“Despite recent therapeutic and surgical advances, the effects of peripheral arterial disease, including heart attack and critical limb ischemia (CLI), remain among the world’s leading causes of morbidity and mortality and represent a rapidly escalating public health crisis,” noted Dr. Xu. “I look forward to presenting a review of our latest findings, including key feasibility study results and an overview of our Phase 3 Critical Limb Ischemia Rapid Stemcell Treatment (CLIRST) trial, which we believe highlight the potential of Cesca Therapeutics’ proprietary AutoXpress® point-of-care platform to deliver autologous cell-based therapies that may represent a new paradigm in patient treatment going forward.”
About the Symposium of Translational Medicine in Stem Cell Myocardial Repair
The 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair brings together more than 650 of the world’s cardiac disease thought leaders to discuss the potential of translational and regenerative medicine in treating myocardial infarction (MI) and cardiac failure. The symposium is co-sponsored by the Shanghai Society for Cell Biology, the Institute of Health Sciences, the Shanghai Cardiovascular Disease Institute, the Guangzhou Institutes of Biomedicine and Health, and the Key Laboratory of Stem Cell Biology, Shanghai.
About Cesca Therapeutics Inc.
Cesca is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. Cesca is an affiliate of the Boyalife Group (http://www.boyalifegroup.com), a China-based industrial-research alliance among top research institutes for stem cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc. [email protected] Investor Contact: Rx Communications Paula Schwartz 917-322-2216 [email protected]
